Is Sofgen Pharma SA halal to invest in?

According to Musaffa's Shariah screening methodology, Sofgen Pharma SA (PROCF) is currently classified as NOT HALAL as of September 2024. The classification is based on an evaluation of the company's business activities and financial ratios to determine whether it meets Islamic investment guidelines.

Is Sofgen Pharma SA a Shariah-compliant stock?

A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Sofgen Pharma SA using these criteria to determine its compliance status.

Can Muslims buy shares of Sofgen Pharma SA?

Muslim investors may consider investing in Sofgen Pharma SA if it meets Shariah compliance standards. Investors typically review the company's business activities, debt levels, and non-permissible income before making a decision.

Why is Sofgen Pharma SA classified as NOT HALAL?

Musaffa determines the Shariah status of Sofgen Pharma SA by analyzing whether the company's core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.

How often is the Shariah compliance for Sofgen Pharma SA updated?

The Shariah compliance status of Sofgen Pharma SA may be updated periodically when new financial statements, earnings reports, or business activity information become available.

Can a halal stock like Sofgen Pharma SA become non-compliant?

Yes. A stock that is currently Shariah-compliant may become non-compliant if the company's financial ratios exceed Shariah thresholds or its business activities change.

Where can I check the Shariah status of Sofgen Pharma SA?

You can check the latest Shariah compliance status of Sofgen Pharma SA on Musaffa's stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.

PROCF Shariah Compliance

Screening Methodology: AAOIFI

NOT HALAL

Last Updated: September 27, 2024

Report Source: 2023 3rd Quarter Report

Sofgen Pharma SA. Stock Analysis PROCF

United States Health Care Micro Cap Report: Q3, 2023

Sofgen Pharma SA is an international healthcare and pharmaceutical company. The firm develops, manufactures and sells prescription drugs and products that are differentiated by their combinations and pharmaceutical forms, as well as nutritional supplements which include omega 3 fish oils and high-potency clinical compounds. The company operates its business through 5 units, which are Diabetrics, Farma Procaps, Softi Gel, Vital Care, and Clinical Specialties. Diabetrics provides diabetes solutions. Manufactures and markets branded prescription drugs in Latin America. Softi Gel provides contract drug development and manufacturing services to third party pharmaceutical companies. Vital Care develops, manufactures and markets consumer healthcare products. Clinical Specialties develops, manufactures and markets complex drugs, solutions, oral antidiabetic medications, and insulin delivery systems.

Key Statistics of Sofgen Pharma SA (PROCF)

Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.

Today's Range

$0.00$0.00

Today's Open

$0.00

Volume

2000.00

P/E Ratio (TTM)

0.02

52 Week Range

$0.00$1.45

Market Cap

55.64M

Avg. Volume

1105.80

Dividend Yield

Financial Metrics & Statements of Sofgen Pharma SA (PROCF)

FAQ's for Sofgen Pharma SA (PROCF)

According to Musaffa’s Shariah screening methodology, Sofgen Pharma SA (PROCF) is currently classified as NOT HALAL as of September 2024. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.